GlycoMira Therapeutics

GlycoMira Therapeutics is a preclinical-stage biopharmaceutical company developing a new class of innate immune system modulators based on polysaccharides that naturally occur within the body. GlycoMira’s dedicated team is working tirelessly toward a vision that will transform the way cancer is treated.  Preclinical development of GlycoMira’s lead drug candidate — GM-1111 — has demonstrated tremendous potential to address unmet needs in solid tumor treatment and supportive care. Employing awards from the National Institutes of Health and private investments, the safety and efficacy of GM-1111 has been shown in preclinical studies.